Practical implication
MAHs should review the updated DRGD to understand new processing timelines for variation submissions and assess how the reliance mechanism can be leveraged for faster safety updates. Adjust internal timelines and processes for post-marketing variation submissions accordingly.
The National Pharmaceutical Regulatory Agency (NPRA) of Malaysia has updated the Drug Registration Guidance Document (DRGD) to include revised processing timelines for variation submissions and to introduce a reliance mechanism for pharmaceutical products. This affects post-marketing safety updates submitted as variations.
What changed: NPRA revised processing timelines for variation applications for all product categories and introduced a reliance mechanism for pharmaceutical products, potentially allowing faster implementation of safety changes already approved by reference agencies.
Why it matters: Variation submissions are the primary vehicle for post-marketing safety labeling updates. Revised timelines may affect the speed of implementation of safety changes, while the reliance mechanism could facilitate quicker adoption of safety updates approved by reference regulators.
Practical implication: MAHs should review the updated DRGD to understand new processing timelines for variation submissions and assess how the reliance mechanism can be leveraged for faster safety updates. Adjust internal timelines and processes for post-marketing variation submissions accordingly.
View original source
Published from the Firecrawl policy change extraction pipeline.
